Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. (2017)

First Author: Harrison CN
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2017-05-785790

PubMed Identifier: 29074595

Publication URI: http://europepmc.org/abstract/MED/29074595

Type: Journal Article/Review

Volume: 130

Parent Publication: Blood

Issue: 17

ISSN: 0006-4971